| Maronan Metals Limited (MMA) ORDINARY FULLY PAID |
Materials |
$116 |
Trading Halt
|
12 Oct 2026 9:02AM |
$0.420 |
$0.370 |
fallen by
11.90%
|
|
MMA - Price-sensitive ASX Announcement
Full Release
Key Points
- ASX placed Maronan Metals Limited (ASX: MMA) into a trading halt on 12 October 2026 at the company’s request.
- The halt was requested pending an announcement by Maronan Metals.
- The company said the announcement related to a material capital raising.
- The trading halt was to remain until the earlier of normal trading commencing on Wednesday, 14 October 2026, or the release of the announcement.
- The request was made under ASX Listing Rule 17.1.
- Maronan Metals stated it was not aware of any reason the trading halt should not be granted.
- The request letter was signed by Ian Gebbie, Company Secretary, on behalf of the board.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| EBR Systems Inc (EBR) CDI 10:1 US PERSON PROHIBITED EXCLUDING QIB |
Health Care |
$110 |
Q3 2026 Commercial Update
|
12 Oct 2026 9:01AM |
$0.235 |
$0.130 |
fallen by
44.68%
|
|
EBR - Price-sensitive ASX Announcement
Full Release
Key Points
- EBR completed 40 WiSE commercial implants in Q3 2026, down from 46 in Q2 2026.
- Total implants across the pilot phase and Limited Market Release reached 157.
- Q3 implant volumes were below forecast, especially in September, due to commercial leadership transition, strategy refocus and extra field training requirements.
- EBR is shifting commercial execution toward deeper utilisation within existing activated accounts rather than opening many new accounts.
- Preliminary unaudited Q3 2026 revenue is expected to be between US$2.43 million and US$2.53 million, compared with US$2.6 million in Q2 2026.
- Five additional purchasing contracts were signed in the quarter, taking the total to 57.
- A total of 100 physicians had been trained to implant the WiSE System, including 10 trained during Q3 2026.
- At 30 September 2026, 40 hospitals had been activated and 20 had completed three or more WiSE implants.
- The final tranche of EBR’s A$150 million capital raising closed in August.
- CMS finalised increased Medicare inpatient reimbursement for eligible WiSE procedures, effective 1 October 2026.
- The new Santa Clara manufacturing facility achieved ISO 13485 certification during Q3 2026.
- The FDA completed its pre-approval inspection of the new Santa Clara facility and issued only two observations on Form 483.
- EBR continues to expect PMA approval for the new manufacturing site by the end of 2026.
- The expanded manufacturing facility has potential capacity of 9,600 systems annually, representing about US$607.6 million in revenue.
- EBR launched the WiSE Coupler, a single-use accessory designed to support catheter positioning and stabilisation during implantation.
- The FDA agreed that no immediate field corrective action or recall was warranted regarding the cybersecurity incident.
- EBR plans to submit a CBE PMA supplement in Q4 2026 to update WiSE labelling relating to echo-induced pacing risk.
- Q4 2026 priorities are improving commercial execution, expanding and training the U.S. field team, increasing procedural frequency and progressing the transition to the new manufacturing facility.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Abacus Group (ABG) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$724 |
Managing Director Retirement and Succession Plan
|
12 Oct 2026 9:00AM |
$0.815 |
$0.810 |
fallen by
0.61%
|
|
| Helia Group Limited (HLI) ORDINARY FULLY PAID |
Financials |
$1,438 |
Update - Notification of buy-back - HLI
|
12 Oct 2026 9:00AM |
$5.340 |
$5.290 |
fallen by
0.94%
|
|
| Dexus Convenience Retail REIT (DXC) FULLY PAID UNITS STAPLED SECURITIES |
Real Estate |
$370 |
Update - Notification of buy-back - DXC
|
12 Oct 2026 9:00AM |
$2.710 |
$2.760 |
risen by
1.85%
|
|
| Regal Investment Fund (RF1) ORDINARY UNITS FULLY PAID |
Financials |
$629 |
Weekly Estimate NTA for 09.10.2026
|
12 Oct 2026 8:59AM |
$3.270 |
$3.010 |
fallen by
7.95%
|
|
| Norwood Systems Limited (NOR) ORDINARY FULLY PAID |
Information Technology |
$9 |
Trading Halt
|
12 Oct 2026 8:59AM |
$0.022 |
$0.016 |
fallen by
27.27%
|
|
NOR - Price-sensitive ASX Announcement
Full Release
Key Points
- ASX placed Norwood Systems Limited (ASX: NOR) into a trading halt on 12 October 2026.
- The trading halt was requested by Norwood Systems Limited.
- The halt was pending the release of an announcement by the company.
- Norwood said the announcement related to a capital raise.
- Unless lifted earlier, the trading halt was to remain until normal trading commenced on Wednesday, 14 October 2026.
- The company stated it was not aware of any reason the trading halt should not be granted.
- Norwood stated there was no other information necessary to inform the market about the trading halt.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Dexus Industria REIT (DXI) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$725 |
Update - Notification of buy-back - DXI
|
12 Oct 2026 8:58AM |
$2.320 |
$2.350 |
risen by
1.29%
|
|
| Capral Limited (CAA) ORDINARY FULLY PAID |
Materials |
$195 |
Notification of cessation of securities - CAA
|
12 Oct 2026 8:58AM |
$12.090 |
$12.390 |
risen by
2.48%
|
|
| Graincorp Limited (GNC) ORDINARY FULLY PAID CLASS A |
Consumer Staple |
$1,400 |
Amended Daily share buy-back notice - Appendix 3E
|
12 Oct 2026 8:58AM |
$6.700 |
$6.450 |
fallen by
3.73%
|
|
| Clover Corporation Limited (CLV) ORDINARY FULLY PAID |
Materials |
$167 |
Change of KMP Interest - Appendix 3Y
|
12 Oct 2026 8:56AM |
$1.000 |
$1.000 |
fallen by
0%
|
|
| Thrive Tribe Technologies Limited (1TT) ORDINARY FULLY PAID |
Information Technology |
$6 |
1TT ADVANCES WOOBOARD CARE 109 PRACTICES EXPRESS INTEREST
|
12 Oct 2026 8:56AM |
$0.001 |
$0.001 |
fallen by
0%
|
|
1TT - Price-sensitive ASX Announcement
Full Release
Key Points
- 1TT received non-binding expressions of interest from 109 allied health practices for WooBoard CARE in the initial Queensland rollout.
- The interested practices comprise 64 physiotherapy practices and 45 psychology practices.
- The location mix is 41 practices on the Gold Coast, 41 in Brisbane and 27 in Ipswich.
- Practices indicated DVA registration and capacity to accept new clients, but all participation is still subject to verification, onboarding and subscription agreement.
- The expressions of interest do not constitute contracted customers or revenue.
- WooBoard CARE is designed to help veterans find providers accepting DVA Veteran Cards and new clients, and to help practices manage veteran enquiries.
- The proposed revenue model combines paid provider listings and enquiry-management tools, while access for veterans will be free.
- The MVP is operational and includes veteran accounts, provider search, appointment-request tracking and provider enquiry tools.
- Platform integration and release testing are targeted for 1 November 2026, subject to final cost approvals and clinical governance input.
- Public launch requires Board approval, minimum verified provider coverage by discipline and location, and a safety framework including crisis routing and clinical sign-off.
- 1TT stated that CARE provides navigation to existing services and does not provide diagnosis, triage, treatment or clinical advice.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Challenger Limited (CGF) ORDINARY FULLY PAID |
Financials |
$7,973 |
Update - Notification of buy-back - CGF
|
12 Oct 2026 8:54AM |
$9.940 |
$11.800 |
risen by
18.71%
|
|
| Regener8 Resources NL (R8R) ORDINARY FULLY PAID |
Materials |
$7 |
Phase 4 Soil Sampling Completed at Srebrenica North
|
12 Oct 2026 8:54AM |
$0.080 |
$0.090 |
risen by
12.50%
|
|
R8R - Price-sensitive ASX Announcement
Full Release
Key Points
- Phase 4 soil sampling at Srebrenica North has been completed with 593 total samples including 30 QAQC samples across the wider Vagan tenement.
- Phase 4 comprised 563 soil samples plus 30 QAQC samples collected at approximately 200 metre spacing along ridgelines and spurs.
- Phase 2 and Phase 3 samples have been submitted to ALS laboratory in Bor, Serbia for analysis.
- Phase 2 included 127 soil samples plus 6 QAQC samples, with additional Phase 2 sampling of about 300 soil samples planned during October 2026.
- Phase 3 sampling is complete with 166 soil samples plus 8 QAQC samples submitted for analysis.
- Phase 1 previously defined three coherent Ag-Zn-Pb-Sb soil anomalies at Chaush, Zanik South and Zanik North.
- Chaush anomaly measures 1,050 metres by 350 metres and remains open to the north-west.
- Zanik South anomaly measures 700 metres by 450 metres, is open to the south and coincides with historical workings.
- Zanik North measures 700 metres by 200 metres and is a newly defined target.
- The Srebrenica North Project comprises the Vagan licence of 49.25 square kilometres and the Dolovi licence of 25.00 square kilometres.
- The project lies within the Srebrenica Volcanic Complex in the Tethyan Metallogenic Belt in eastern Bosnia and Herzegovina.
- The nearby operating Sase mine is about 1 kilometre south-east of the Chaush anomaly, but the company states this does not indicate economic mineralisation at the project.
- Ground magnetic surveying over the Zanik and Gradina areas has been completed and interpretation is in progress.
- Regener8 plans to integrate soil geochemistry and magnetic data to rank targets for mapping, rock chip sampling, trenching and first-pass drilling subject to results and approvals.
- The company states the project has not been drilled by Regener8 and no Mineral Resource or Ore Reserve has been estimated.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Orora Limited (ORA) ORDINARY FULLY PAID |
Materials |
$1,833 |
Update - Notification of buy-back - ORA
|
12 Oct 2026 8:53AM |
$1.410 |
$1.500 |
risen by
6.38%
|
|
| Growthpoint Properties Australia (GOZ) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$1,468 |
GOZ 2026 Notice of Annual General Meeting
|
12 Oct 2026 8:52AM |
$1.930 |
$1.945 |
risen by
0.78%
|
|
| Racura Oncology Ltd (RAC) ORDINARY FULLY PAID |
Health Care |
$299 |
HARNESS-1 First Cohort Cleared
|
12 Oct 2026 8:51AM |
$1.815 |
$1.525 |
fallen by
15.98%
|
|
RAC - Price-sensitive ASX Announcement
Full Release
Key Points
- Racura announced SRC clearance for HARNESS-1 to escalate RC220 to 100 mg/m2.
- The HARNESS-1 trial is evaluating RC220 with osimertinib in EGFR-mutant non-small cell lung cancer.
- The SRC reviewed safety data from both Cohort 1 patients treated at 50 mg/m2 RC220 plus osimertinib 80 mg daily.
- Neither Cohort 1 patient experienced dose-limiting toxicity or other treatment-related safety concerns during the safety observation period.
- The second Cohort 1 patient received three RC220 doses 21 days apart without dose-limiting toxicities or treatment-related safety concerns.
- A second patient was added to Cohort 1 after the first patient experienced Grade 2 colitis outside the safety observation period.
- Racura said the cause of the colitis could not be determined and RC220 could not be excluded by the SRC.
- Pre-screening is underway for the single Cohort 2 patient, who will receive RC220 at 100 mg/m2.
- The company emphasised that dose-escalation clearance does not demonstrate efficacy or prove RC220 is safe and effective overall.
- HARNESS-1 uses an accelerated titration design for the first three dose levels of 50, 100 and 150 mg/m2 before potentially transitioning to a BOIN design at 200 mg/m2.
- Racura said future market updates will depend on trial progress, including enrolment, dosing, safety review, dose escalation and any early efficacy signals.
- CEO and Managing Director Dr Daniel Tillett described the SRC clearance as an important early milestone in the HARNESS-1 clinical development plan.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Boom Logistics Limited (BOL) ORDINARY FULLY PAID |
Industrials |
$80 |
Update - Notification of buy-back - BOL
|
12 Oct 2026 8:48AM |
$2.440 |
$2.210 |
fallen by
9.43%
|
|
| Hamelin Gold Limited (HMG) ORDINARY FULLY PAID |
Materials |
$49 |
Quarterly Activities Report and Appendix 5B
|
12 Oct 2026 8:48AM |
$0.225 |
$0.195 |
fallen by
13.33%
|
|
HMG - Price-sensitive ASX Announcement
Full Release
Key Points
- Quarterly report and Appendix 5B cover the period ended 30 September 2026 and were announced on 12 October 2026.
- Day Dawn in the Paterson Province was the key exploration focus during the quarter.
- Phase 1 RC drilling at Day Dawn completed 28 holes and confirmed two high-grade gold lodes at Aurora.
- Key Aurora intercepts included 3m at 93.4 g/t Au from 9m, 3m at 17.1 g/t Au from 17m, 4m at 21.0 g/t Au from 27m and 2m at 12.4 g/t Au from 149m.
- Altus drilling identified a previously unrecognised reef-style gold mineralisation system open in all directions.
- The Altus result included 1m at 21.5 g/t Au from 24m in PDR0005.
- Phase 2 RC drilling at Day Dawn was expanded from about 3,000m to about 4,000m across 35 holes.
- Phase 2 assay results were expected in October 2026.
- Diamond drilling at Day Dawn was scheduled to commence in October 2026.
- Hamelin received up to $180,000 in WA EIS co-funded support for diamond drilling at Day Dawn.
- Venus Project target refinement identified Veritas, Mariner and Davinci as priority undercover gold prospects beneath Lake Austin.
- A heritage survey at Venus was completed with clearance granted for planned drilling access and aircore traverses.
- An initial 130-hole aircore drilling program at Venus was scheduled for early 2027.
- At West Tanami, follow-up drilling is planned at Jazz and Fremlins South.
- Fremlins South has a shallow gold zone over more than 400 metres strike and remains open at depth.
- Jazz drilling outlined broad shallow north-dipping low-grade gold mineralisation over more than 500 metres strike with potential for higher-grade shoots.
- Hamelin lodged four new exploration licence applications since the beginning of 2026 across the Tanami, Paterson and Yilgarn provinces.
- The company held cash reserves of about $9.0 million at 30 September 2026, reported as $8.961 million in Appendix 5B.
- Hamelin completed an approximately $8 million share placement at $0.16 per share before costs.
- Placement support included major shareholders Gold Fields Limited and Vault Minerals Limited.
- Quarterly exploration expenditure was $863,000, predominantly at the wholly owned Day Dawn project.
- Net cash used in operating activities was $214,000 for the quarter.
- Net cash used in investing activities was $863,000 for the quarter.
- Net cash from financing activities was $7.555 million after transaction costs.
- There were no loan facilities or other financing facilities drawn at quarter end.
- Related-party payments totalled $89,000 in operating cash flows and $85,000 in investing cash flows.
- The tenement schedule showed E58/654 at Venus moving from 0% to 100% during the quarter.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Mirvac Group (MGR) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$7,006 |
Update - Notification of buy-back - MGR
|
12 Oct 2026 8:48AM |
$1.840 |
$1.805 |
fallen by
1.90%
|
|
| Xero Limited (XRO) ORDINARY FULLY PAID |
Information Technology |
$10,932 |
Initial Directors Interest Notice - Mark Durcan
|
12 Oct 2026 8:47AM |
$59.810 |
$64.060 |
risen by
7.11%
|
|
| OD6 Metals Limited (OD6) ORDINARY FULLY PAID |
Materials |
$31 |
OD6 COMPLETES A$6.92 MILLION PLACEMENT
|
12 Oct 2026 8:46AM |
$0.094 |
$0.084 |
fallen by
10.64%
|
|
OD6 - Price-sensitive ASX Announcement
Full Release
Key Points
- OD6 completed an A$6.92 million placement before costs.
- The placement involved issuing approximately 72.84 million new fully paid ordinary shares at A$0.095 per share.
- Funds have been received and the placement shares have been issued.
- The raising was supported by global institutional investors, family offices, and sophisticated and professional investors.
- The placement strengthens OD6’s balance sheet and funding position.
- Proceeds will primarily fund maiden drilling and bulk sampling at the Quinn Fluorspar Project, subject to approvals.
- Funds will also support metallurgical testwork, assaying, geological modelling, resource definition, ongoing permitting, broader portfolio activities, and general working capital.
- OD6 said it is advancing its critical minerals strategy across Quinn, Splinter Rock, and Gulf Creek.
- Management highlighted upcoming catalysts including Quinn permitting and drilling, further ANSTO testwork results at Splinter Rock, and ongoing work at Gulf Creek.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| AXP Energy Limited (AXP) ORDINARY FULLY PAID |
Energy |
$2 |
Entitlement Issue Prospectus
|
12 Oct 2026 8:46AM |
$0.005 |
$0.004 |
fallen by
20%
|
|
AXP - Price-sensitive ASX Announcement
Full Release
Key Points
- Prospectus dated 9 October 2026 for an entitlement issue by AXP Energy Limited.
- Offer is a 1-for-1 non-renounceable entitlement issue at $0.005 per share.
- Eligible shareholders receive 1 new option for every 2 shares subscribed.
- Maximum capital sought under the entitlement offer is $2,248,668 and minimum subscription is $1.2 million.
- Lead manager offer includes up to 89,946,706 new options to Alpine Capital Pty Ltd or its nominees.
- Funds are intended for a contiguous project acquisition, well recompletions, loan repayment, placement fees, working capital and offer costs.
- Record date is 15 October 2026 and closing date is 3 November 2026 unless extended.
- If fully subscribed, issued shares would rise to 899,467,060.
- New options are exercisable at $0.01 and expire 2 years from issue.
- Non-participating shareholders may face about 50% dilution, and about 60% if the new options are exercised.
- The board states the company will have sufficient working capital on completion of the raising, but going concern risk remains if the offer is unsuccessful.
- Key risks include going concern uncertainty, unsecured cash advances, need for further funding, regulatory approvals, operational and drilling risks, gas-to-power execution risk, climate and weather risks, and a potential Colorado environmental fine.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Aroa Biosurgery Limited (ARX) ORDINARY FULLY PAID |
Health Care |
$182 |
Investor Presentation - Symphony RCT
|
12 Oct 2026 8:46AM |
$0.520 |
$0.525 |
risen by
0.96%
|
|
| Growthpoint Properties Australia (GOZ) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$1,468 |
GOZ - Changes to the Board
|
12 Oct 2026 8:45AM |
$1.930 |
$1.945 |
risen by
0.78%
|
|
Call 1300 880 160
Start a chat
Schedule a call
